24 May 2013
Keywords: Protalix, Taliglucerase, Gaucher disease, Pfizer, USA, FDA
Article | 02 August 2011
USA-based Protalix BioTherapeutics (NYSE-AMEX: PLX) says it has submitted its reply to the Complete Response Letter issued by the Food ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 August 2011
1 August 2011
23 May 2013
© 2013 thepharmaletter.com